Gastrointestinal stromal tumor
Conditions
Interventions
Imatinib treatment group:NA
Sponsors
Harbin Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years old, diagnosed as gastrointestinal stromal tumor through pathological histology and immunohistochemical examination. 2. Take imatinib continuously and regularly for more than a month, and follow the doctor's advice daily without any missed medication, and achieve a stable blood drug concentration. 3. Those with complete clinical data and complete follow-up information shall undergo clinical follow-up on time. 4. Signed an informed consent form and conducted regular outpatient follow-up. 5. The treatment compliance is good, and there are no serious diseases in other important organs.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, patients with extremely poor mental and physical conditions; 2. Oral administration of imatinib mesylate is less than one month, and the expected overall survival period is less than three months; 3. Simultaneously taking other targeted drugs while taking imatinib mesylate; 4. Individuals with a history of mental illness or symptoms of abnormal mental state; 5. Patients who experience imatinib resistance or treatment intolerance and terminate treatment; 6. Individuals who have participated in clinical trials of other drugs for the past three months or are currently participating in such trials; Simultaneously taking CYP3A4 inducers or inhibitors; Common CYP3A4 inducers include rifampicin, rifampicin, phenytoin, carbamazepine, barbiturates, or St. John's wort. Common CYP3A4 inhibitors include itraconazole, ketoconazole, voriconazole, azavir, ritonavir, clarithromycin, grapefruit, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of steady-state trough concentration after treatment with imatinib 400mg/d;The correlation between steady-state trough concentration distribution of imatinib and efficacy/safety in Chinese population; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;Disease control rate;progression-free survival;overall survival;safety; | — |
Countries
China
Contacts
Public ContactMei Dong
Harbin Medical University Cancer Hospital
Outcome results
None listed